PCT

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ^{6} : C12N 15/54, C12P 13/22, 19/02, 1/00, C12N 15/31, C07H 11/04, C12N 1/21 // C12Q 1/48, (C12N 1/21, C12R 1:07, 1:13, 1:15, 1:185, 1:19, 1:425)	**A1**	(11) International Publication Number: **WO 98/18936**
		(43) International Publication Date: 7 May 1998 (07.05.98)

(54) Title: MICROBIAL PREPARATION OF SUBSTANCES FROM AROMATIC METABOLISM/I

(57) Abstract

The invention makes available, by means of an increased provision of intracellular metabolic intermediates, in particular of erythrose 4–phosphate, alternative processes for the microbial preparation of substances, in particular of aromatic amino acids such as L–phenylalanine, in which processes the activity of a transaldolase is increased in a microorganism producing these substances. In preferred embodiments of the invention, the activity of a transketolase or the activity of a transport protein for the PEP–independent uptake of a sugar and/or the activity of a kinase which phosporylates the relevant sugar are/is additionally increased. The invention also relates to gene structures, and to transformed cells carrying these gene structures, which make it possible to implement these processes in a particularly successful manner.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

MICROBIAL PREPARATION OF SUBSTANCES
FROM AROMATIC METABOLISM/I

5

The invention relates to a process for the microbial preparation of substances, in particular aromatic amino acids, according to Claims 1-23, 36 and 37, to gene structures according to Claims 24-29, and to

10 transformed cells according to Claims 30-35.

Microbially prepared substances, such as fine chemicals, in particular aromatic amino acids, are of great economic interest, with the requirement for amino acids, for example, continuing to increase. Thus,

15 L-phenylalanine, for example, is used for preparing medicaments and, in particular, also in the preparation of the sweetener aspartame (α-L-aspartyl-L-phenylalanine methyl ester). L-tryptophan is required as a medicament and as an additive to animal feeds; there is likewise a

20 need for L-tyrosine as a medicament and also as a raw material in the pharmaceutical industry. In addition to isolation from natural materials, biotechnological preparation is a very important method for obtaining amino acids in the desired optically active form under

25 economically justifiable conditions. Biotechnological preparation is effected either using enzymes or using microorganisms. The latter, microbial, preparation enjoys the advantage that simple and inexpensive raw materials can be employed. Since the biosynthesis of amino acids in

30 the cell is controlled in a wide variety of ways, however, a large number of attempts have already been made to increase product formation. Thus, amino acid analogues, for example, have been employed in order to switch off the regulation of biosynthesis. For example, mutants of

35 *Escherichia coli* permitting an increased production of L-phenylalanine were obtained by selecting for resistance to phenylalanine analogues (GB-2,053,906). A similar strategy

also led to overproducing strains of *Corynebacterium*
(JP-19037/1976 and JP-39517/1978) and *Bacillus*
(EP-0,138,526). Furthermore, microorganisms which have
been constructed using recombinant DNA techniques are
5   known in which the regulation of biosynthesis is likewise
abolished, with the genes which encode key enzymes which
are no longer subject to feedback inhibition being cloned
and expressed. As a prototype, EP-0,077,196 describes a
process for producing aromatic amino acids in which a 3-
10 deoxy-D-arabinoheptulosonate-7-phosphate synthase (DAHP
synthase) which is no longer subject to feedback inhi-
bition is overexpressed in *E. coli*. EP-0,145,156 describes
an *E. coli* strain in which chorismate mutase/prephenate
dehydratase are additionally overexpressed for the purpose
15 of producing L-phenylalanine.

A feature common to the abovementioned
strategies is that the intervention for improving
production is restricted to the biosynthesis pathway which
is specific for the aromatic amino acids. However, in
20 order to increase production still further, efforts must
be made to improve the provision of the primary
metabolites, phosphoenolpyruvate (PEP) and erythrose 4-
phosphate (Ery4P), which are required for producing
aromatic amino acids.

25   PEP is an activated precursor of the glycolysis
product pyruvate; Ery4P is an intermediate in the pentose
phosphate pathway.

Various attempts have been made to achieve a
specific improvement in the provision of the said primary
30 metabolite Ery4P. An increased flow of carbon through the
pentose phosphate pathway was achieved in *E. coli* by
switching off the enzyme phosphoglucose isomerase; this
resulted in tryptophan being formed (Mascarenhas D. et
al., Appl. Environ. Microbiol. 57 (1991) 2995-99).

- 3 -

US-A-5,168,056 disclosed that overexpression of a trans-
ketolase, achieved by means of recombinant DNA techniques,
makes it possible to obtain an increased provision of
Ery4P and, as a consequence, an improvement in the
5   formation of L-tryptophan, L-tyrosine or L-phenylalanine
as products. Both Draths K.M. et al. (J. Am. Chem. Soc.
114 (1992) 3956-62) and Flores N. et al. (Nat. Biotechnol.
14 (1996) 620-3) demonstrated the same effect. However, as
Feldmann has shown, simply increasing the activity of
10 transketolase in *Zymomonas mobilis* strains lacking
transaldolase activity leads to the enrichment of
metabolites of the pentose phosphate pathway in the cells
and, as a consequence, to negative effects on cell growth
(Feldmann S.D. et al., Appl. Microbiol. Biotechnol. 38
15 (1992) 354-61). This physiological effect may possibly be
attributable to an excessive intracellular concentration
of sedoheptulose-7-phosphate. The inventors have also
found a corresponding inhibition of biomass growth as a
consequence of transketolase overexpression in the case of
20 *E. coli* tal⁻ strains.

The object of the invention is, therefore, to
make available an alternative process for producing
substances, in particular aromatic amino acids, which
process is distinguished by an increased provision of
25 intracellular metabolic intermediates for the synthesis of
these substances without suffering from the above-cited
disadvantages of the processes, which disadvantages are
the consequence of only increasing the activity of the
transketolase.

30 Surprisingly, this object is achieved, according
to the invention, by making available a process for the
microbial preparation of substances, in which process the
activity of a transaldolase is increased in a micro-
organism which is producing these substances, with the

activity of a phosphoenolpyruvate (PEP)-dependent sugar-uptake system in this microorganism being present, reduced or absent.

This result is particularly surprising in that it is in no way self-evident that transaldolases play an important role in the growth of microorganisms and in their production of substances. This particularly applies in the case of growth on hexoses. Thus, yeast strains are known, for example, which are still able to grow on glucose despite having a mutation in the transaldolase gene (Schaaff L. et al., Eur. J. Biochem. 188 (1990) 597-603). Accordingly, a transaldolase should not exert any essential influence on cell growth. This is supported by the fact that bacterial species are also known which are able to grow in the absence of a transaldolase (Feldmann S.D. et al., Appl. Microbiol. Biotechnol. 38 (1992) 354-62).

In addition, hexoses such as glucose, in contrast to xylose and other pentoses, can also be metabolized through degradation pathways other than the pentose phosphate pathway. It is therefore in no way self-evident that transaldolase has an essential function in glucose degradation.

It may also be noted that an increased flow by way of the enzymes of the pentose phosphate pathway was measured in vitro in extracts of *Saccharomyces cerevisiae* cells in which the activity of a transaldolase was increased (Senac T. et al., Appl. Environ. Microbiol. 57 (1991) 1701-6). However, the experimental conditions which were selected in this study do not permit any transfer of the results to the natural phenomena of metabolic physiology which occur in living microorganisms, in particular bacteria. In addition, it may be noted that Liao J.C. et al. (Biotechn. Bioeng. 52 (1996) 129-140 have

shown that when the activities of a transaldolase and AroG
are simultaneously increased, DAHP formation increases.
This effect is to be ascribed mainly to the increase in
AroG activity. An increase in the production of substances
5   as a result of an increase in transaldolase activity as
such is not disclosed or indicated. It is therefore in no
way to be expected that there is a causal relationship
between an increase in transaldolase activity in
microorganisms and the provision of Ery4P for the improved
10   production of substances. Increasing the activity
(overexpression) of a transaldolase in accordance with the
present invention makes available an alternative process
for implementing an increased flow of carbon through the
pentose phosphate pathway and consequently effecting an
15   improved provision of the primary metabolite Ery4P. An
increased quantity of Ery4P is consequently available for
the microbial synthesis of substances in whose synthesis
at least one intermediate of the pentose phosphate
pathway, and in particular Ery4P, is involved. The
20   inventors have shown that the improved availability of
Ery4P occurs both in microorganisms in which the activity
of a PEP-dependent sugar-uptake system is present or
reduced and in microorganisms in which such an activity is
absent. Thus, according to the invention not only
25   organisms which still have active phosphotransferase
systems (PTS) or phosphotransferase systems with reduced
activity (pts' strains) may be used but also organisms in
which the PTS has been switched off (pts⁻ strains).
          Within the meaning of the invention, substances
30   are to be understood as being, for example, fine chemicals
such as aromatic amino acids, indigo, indoleacetic acid,
adipic acid, melanin, quinones and benzoic acid, and also
their potential derivatives and secondary products - or,
in a general manner, secondary products of intermediates

of the pentose phosphate pathway. However, this should
also include all the compounds, for example pyridoxine and
its derivatives, whose biochemical synthesis is promoted
by the provision of erythrose 4-phosphate. Within the
5   context of this invention, all these substances are also
regarded as being substances from aromatic metabolism. It
may be noted in this context that further genetic
alterations to the substance-producing microorganisms are
required, in addition to the novel interventions, for
10   preparing indigo, adipic acid and other unnatural
secondary products. The process according to the invention
is particularly suitable for the preparation of substances
in microorganisms which have not, prior to the increasing
of the transaldolase activity, been selected as strains
15   with a switched-off phosphotransferase system (pts⁻
strains) from strains which previously harboured a
phosphotransferase system (pts⁺ strains). In this
connection it may be noted that the non-prepublished
patent specification WO-96/34961 describes such a
20   selection from what were previously pts⁺ strains, but in
this study this selection precedes the increasing of the
transketolase or transaldolase activity.

      With regard to increasing the activity of a
transaldolase, preference is given to increasing the
25   activity of an *Escherichia coli* transaldolase and, in
particular, the activity of *Escherichia coli* transaldolase
B (TalB). When the corresponding talB gene is used, this
gene preferably originates from *Escherichia coli* K12 or
from a strain which is derived therefrom. Besides this,
30   however, any gene is also suitable whose gene product
catalyses a reaction which corresponds to that of
transaldolase, that is the conversion of sedoheptulose
7-phosphate plus glyceraldehyde 3-phosphate to Ery4P and
fructose-6-phosphate.

In a particularly advantageous embodiment of the
invention, the activity of a transketolase is increased in
addition to increasing the activity of a transaldolase. In
the presence of pentoses, the expression of a

5   transketolase gene on its own leads to a build up of
metabolites in the pentose phosphate pathway
(Feldmann S.D., Appl. Microbiol. Biotechnol. 38 (1992)
354-61). This has a harmful effect on the cell and
results, inter alia, in the transformed cells growing at a

10   diminished rate. The inventors also observed an identical
effect in the case of an *Escherichia coli* strain which was
growing on glucose and which exhibited increased
transketolase activity. However, simultaneously increasing
the activity of a transketolase as well as that of a

15   transaldolase has now been found to be very beneficial for
providing Ery4P and does not exhibit the negative side
effects of a sole overexpression of a transketolase. The
accumulation of metabolites of the pentose phosphate
pathway which occurs when the activity of a transketolase

20   is increased consequently fails to materialize as a result
of increasing the activity of a transaldolase, as the
result of which the impairment in the growth of the cells
is not only halted but even converted into an increase in
growth. It turns out, therefore, that increasing the

25   activity of a transketolase particularly in strains having
an increased activity of transaldolase in accordance with
the invention is a sensible measure.

         With regard to increasing the activity of a
transketolase, preference is given to increasing the

30   activity of an *Escherichia coli* transketolase and, in
particular, the activity of *Escherichia coli* transketolase
A (TktA). When the corresponding tktA gene is used, this
gene preferably originates from *Escherichia coli* K12 or
from a strain which is derived therefrom. In addition to

this, however, any gene is also suitable whose gene
product catalyses a reaction which corresponds to that of
transketolase, that is the conversion of ribose
5-phosphate plus xylulose 5-phosphate to sedoheptulose
5   7-phosphate plus glyceraldehyde 3-phosphate or the
conversion of xylulose 5-phosphate plus Ery4P to fructose
6-phosphate plus glyceraldehyde 3-phosphate.

In another particularly preferred embodiment of
the invention, the activity of a transport protein for the
10   PEP-independent uptake of a sugar and/or the activity of a
kinase which phosphorylates the corresponding sugar is/are
increased in addition to increasing the activity of a
transaldolase or increasing the activity of a
transaldolase and a transketolase. In the case of the
15   transport protein, the activity of this protein is
understood as being the protein-mediated uptake rate. The
additional increase in the activity of one of these latter
proteins, i.e. the transport protein and the kinase, or of
both proteins makes it possible to achieve an even higher
20   production of substances, in particular aromatic amino
acids, due to the fact that PEP is provided in increased
quantity for the condensation with Ery4P to form the
primary metabolite of the general pathway for
biosynthesizing aromatic compounds, i.e. deoxy-D-
25   arabinoheptulosonate-7-phosphate (DAHP).

It is advisable to use a facilitator as the
transport protein for the PEP-independent uptake of a
sugar, that is a transport protein which acts in accor-
dance with the principle of protein-mediated facilitated
30   diffusion. In particular, it is suitable to use the
glucose facilitator protein (Glf) from *Zymomonas mobilis*.
When the latter is used, the protein-encoding gene, *glf*,
is obtained, for example, from *Z. mobilis* ATCC 10988, ATCC
29191 or ATCC 31821. However, other bacterial sugar

- 9 -

transport genes whose gene products transport glucose,
fructose or sucrose, for example, and in doing so do not
use any PEP, for example the GalP system from *Escherichia*
coli, are also suitable for the novel process. Genes for
5   sugar transport systems, such as HXT1 to HXT7, from
eukaryotic microorganisms, such as *Saccharomyces*
cerevisiae, *Pichia stipitis* or *Kluyveromyces lactis*, or
sugar transport genes from other organisms in general, can
also be used, provided that they can be expressed in a
10 functional manner in the microorganisms and that the gene
products can, in this context, operate without using PEP
for transporting the sugars. It is particularly advisable
for it to be possible to express the sugar transport genes
in amino acid-producing microorganisms (amino acid
15 producers).

It is particularly suitable, therefore, to use
the facilitator gene *glf*, isolated from *Z. mobilis* ATCC
31821, for taking up sugars such as glucose, fructose or
mannose when preparing aromatic amino acids in accordance
20 with the novel process. (Parker C. et al., Mol. Microbiol.
15 (1995) 795-802; Weisser P. et al., J. Bacteriol. 177
(1995) 3351-4). The process according to the invention is
particularly suitable for the preparation of aromatic
amino acids in microorganisms in which the PTS system has
25 a reduced activity or is completely absent. In such cases
the PTS system may be reduced or switched off before but
also after the increasing of the transaldolase activity.

The *glf* gene, in particular, should preferably
be inserted at a low gene copy number in order to avoid
30 harmful effects on the cell due to excessive expression of
membrane proteins. Thus, a gene copy number of from 2 to 5
is preferred, for example, for the *glf* gene. It is
particularly advantageous to insert the *glf* gene into one
of the genes of the *pts*HI-crr operon, for example into the

ptsI gene.

When a sugar-phosphorylating kinase is being employed, it is advisable to use a hexose-phosphorylating kinase, preferably a kinase, in particular glucokinase

5   (Glk), from *Zymomonas mobilis*. When the latter is used, the protein-encoding gene, *glk*, is derived, for example, from *Z. mobilis* ATCC 10988, ATCC 29191 or ATCC 31821. Other genes for hexose-phosphorylating kinases from bacteria whose gene products phosphorylate hexoses while

10   consuming ATP, such as a fructokinase or a mannokinase, are likewise suitable for the novel process. Furthermore, genes for, for example, kinases from eukaryotic micro-organisms, such as *Saccharomyces cerevisiae*, or, in a general manner, genes for sugar-phosphorylating kinases

15   from other organisms, are also suitable, provided they can be expressed in a functional manner in the microorganisms, in particular amino acid producers, and can operate without using PEP to phosphorylate the sugars. The glucokinase gene, *glk*, for phosphorylating glucose,

20   which gene is isolated from *Z. mobilis* ATCC 29191, is particularly suitable for preparing aromatic amino acids in accordance with the novel process.

The availability of PEP for producing the first intermediate of aromatic amino acid metabolism can be

25   limited in microorganisms in which the flow of material towards Ery4P is increased. In these cases, it can be advantageous to reduce, or completely switch off, other PEP-consuming reactions in the metabolism, such as the reaction of the PEP:sugar phosphotransferase system (PTS),

30   which catalyses a PEP-dependent sugar uptake, if this system is present. According to the invention, use can be made both of organisms which still possess active PTS genes (*pts*⁺ strains) and, for the further improvement of the process, of *pts* mutants in which the activity of the

pts is decreased (also to be considered as *pts'* in the present case) or in which the *pts* is switched off (*pts⁻* strains). A decrease of this nature can either be effected at the enzymic level or by using genetic methods, for

5   example by inserting a *glf* and/or a *glk* gene into the chromosome and, in particular, into the locus of the *ptsI* gene, a procedure which simultaneously stabilizes the recombinant DNA in the chromosome (segregation stability) and consequently means that the use of a vector can be

10   dispensed with. The inventors' experiences have shown that reducing or switching off the activity of the PTS should preferably not take place before the activity of the transaldolase is increased.

          Within the meaning of the invention, measures

15   for increasing the activity are to be understood as being all measures which are suitable for increasing the activity of the transaldolase, of the transketolase, of the transport protein, and of the kinase. The following measures are particularly suitable for this purpose:

20   - introduction of genes, for example using vectors or temperate phages;
- increasing the gene copy number, for example using plasmids with the aim of introducing the genes according to the invention into the microorganism at an increased

25   copy number, that is at a copy number which is slightly (e.g. from 2 to 5 times) increased to highly (e.g. from 15 to 50 times) increased;
- increasing gene expression, for example by increasing the rate of transcription, for example by using promoter

30   elements such as P*tac*, P*tet* or other regulatory nucleotide sequences, and/or by increasing the rate of translation, for example by using a consensus ribosome binding site;
- increasing the endogenous activity of enzymes which are present, for example by means of mutations which are

- 12 -

produced in a random manner by conventional methods, for
example using UV irradiation or mutation-eliciting
chemicals, or by means of mutations, such as deletion(s),
insertion(s) and/or nucleotide exchange(s), which are
5   produced in a specific manner using genetic engineering
methods;
- increasing the activity of enzymes by altering the
structure of enzymes, for example by means of mutagenesis
using physical, chemical or molecular biological or other
10   microbiological methods;
- using deregulated enzymes, for example enzymes which are
no longer subject to feedback inhibition;
- introduction of corresponding genes which encode the
deregulated enzymes.
15   Combinations of the abovementioned methods and
other, analogous methods can also be employed for
increasing the activity. The endogenous or introduced
activity of transport proteins can be increased, for
example, by cloning the gene using the abovementioned
20   methods, for example, or by selecting mutants which
exhibit an increased transport of substrates.
            Preferably, the activity is increased by inte-
grating the gene, or the genes, into a gene structure, or
into several gene structures, with each gene or the genes
25   being introduced into the gene structure as (a) single
copy(ies) or at an increased copy number.
Within the meaning of the invention, a gene structure is
to be understood as being a gene and any other nucleotide
sequence which carries the genes according to the
30   invention. Appropriate nucleotide sequences can, for
example, be plasmids, vectors, chromosomes, phages or
other nucleotide sequences which are not closed
circularly.
            A chromosome within the meaning of the invention

- 13 -

is a chromosome into which at least one gene according to
the invention has been inserted, with the resulting
nucleic acid sequence containing at least one gene, or one
gene copy, more than is naturally contained in this
5   chromosome. On the other hand, for example, homologous
recombination within a gene locus leads to a chromosome
which does not necessarily have to differ from the natural
form. The chromosomes which are prepared by homologous
recombination are not, therefore, to be regarded as being
10 in accordance with the invention if the natural number of
homologous genes is not exceeded.

Within the meaning of the invention, a gene
structure is also to be understood as being a combination
of the abovementioned gene carriers, such as vectors,
15 chromosomes and temperate phages, on which the genes
according to the invention are distributed. For example,
two *tal* genes can be introduced into the cell on a vector
or two *tal* genes can be inserted into a chromosome. In
addition, a further gene can, for example, be introduced
20 into the cell using a phage. The same applies to the other
genes according to the invention. These examples are not
intended to exclude other combinations of gene
distributions from the invention. In any case, it is
crucial that the number of genes contained in the
25 microorganism according to the invention exceeds the
natural number of the corresponding genes. Preferably, the
number of *glf* genes, for example, will be increased by a
factor of from 2 to 5 in order to achieve the increase in
activity according to the invention. No cell-toxic effect
30 will appear at these concentrations. However, it is also
conceivable to introduce the genes according to the
invention into the microorganism at a higher copy number
of up to 50 gene copies of a form having the same effect.

In the novel process for producing substances,

- 14 -

preference is given to employing microorganisms in which one or more enzymes which are additionally involved in synthesizing the substances are deregulated and/or have an increased activity.

5   These enzymes are, in particular, the enzymes of aromatic amino acid metabolism and, especially, DAHP synthase, shikimate kinase and chorismate mutase/prephenate dehydratase, and also all the other enzymes which are involved in synthesizing intermediates

10 of aromatic metabolism and their secondary products.

Apart from the enzymes according to the invention, the deregulation and overexpression of DAHP synthase in particular is of importance for preparing substances such as adipic acid, bile acid and quinone

15 compounds and their derivatives. In addition, shikimate kinase should be deregulated, and its activity increased, in order to achieve superelevated synthesis of, for example, tryptophan, tyrosine, indigo and derivatives of hydroxybenzoic acid and aminobenzoic acid and naphtho-

20 quinones and anthroquinones and also their secondary products. Deregulated and overexpressed chorismate mutase/prephenate dehydratase is additionally of par-ticular importance for efficiently producing phenylalanine and phenylpyruvic acid and their derivatives. However,

25 this is also intended to encompass all the other enzymes whose activities contribute to the biochemical synthesis of substances, that is compounds whose production is promoted by the provision of erythrose 4-phosphate, for example pyridoxine and its derivatives. It may be noted

30 that further genetic alterations to the substance-producing microorganisms, in addition to the novel interventions, are required for the purpose of preparing indigo, adipic acid and other unnatural secondary products.

The novel process is suitable, in particular, for preparing aromatic amino acids, in particular phenyl-alanine. In the latter case, the gene expression and/or the enzyme activity of a deregulated DAHP synthase (e.g.
5 in *E. coli* AroF or AroH) and/or of a likewise deregulated chorismate mutase/prephenate dehydratase (PheA) is preferably increased.

Escherichia species, and also microorganisms of the genera *Serratia*, *Bacillus*, *Corynebacterium* or *Brevi-*
10 *bacterium*, and other strains which are known from conven-tional amino acid methods, are suitable for use as production organisms. *Escherichia coli* is particularly suitable.

Another object of the invention is to provide
15 suitable gene structures, and transformed cells carrying these gene structures, which enable the process to be implemented in a particularly successful manner. Within the context of the invention, novel gene structures are now made available, which gene structures contain, in
20 recombinant form, a) a gene encoding a transaldolase or a gene encoding a transaldolase and a gene encoding a transketolase, and b) at least one gene encoding a transport protein for the PEP-independent uptake of a sugar or encoding a kinase which phosphorylates a sugar.
25 In these gene structures, it is preferred that the gene for the transport protein encode a facilitator and the gene for the kinase encode a hexose-phosphorylating kinase. In particular, the genes for the transaldolase and the transketolase are derived from *Escherichia coli* and
30 the genes for the transport protein and the kinase are derived from *Zymomonas mobilis*.

Gene structures are particularly advantageous in which the gene for the transaldolase is *Escherichia coli* *tal*B and the gene for the transketolase is *Escherichia*

*coli tkt*A, while the gene for the transport protein is
Zymomonas mobilis glf and the gene for the kinase is
Zymomonas mobilis glk.

The appropriate genes are isolated, and the
5   cells are transformed, in accordance with current methods:
the complete nucleotide sequences of the *talB* and *tktA*
genes from *Escherichia coli* K12 are known (Yura T. et al.,
Nucl. Acid Res. 20 (1992) 3305-8; Sprenger G.A., Biochim.
Biophys. Acta 1216 (1993) 307-10; Sprenger G.A. et al., J.
10 Bacteriol. 177 (1995) 5930-9) and deposited in databases
such as that of the EMBL in Heidelberg. When the
Escherichia coli talB gene is being cloned, the polymerase
chain reaction (PCR) method is suitable, for example, for
specifically amplifying the gene using chromosomal DNA
15 from *Escherichia coli* K12 strains (Sprenger G.A. et al.,
J. Bacteriol. 177 (1995) 5930-9). The homologous
complementation of a transketolase-deficient mutant is
suitable, for example, when cloning the *Escherichia coli
tktA* gene (Sprenger G.A. in: Bisswanger H. et al.,
20 Biochemistry and physiology of thiamine diphosphate
enzymes, VCH (1991) 322-6).

When cloning the *Zymomonas mobilis* transport
gene *glf* or the *Zymomonas mobilis* glucokinase gene *glk*,
for example, PCR, for example, is suitable for
25 specifically amplifying the gene using chromosomal DNA
from *Zymomonas mobilis* strains ATCC 29191 or ATCC 31821,
as is also the heterologous complementation of *Escherichia
coli* mutants which are defective in PTS functions and
which are therefore unable to transport glucose, for
30 example (Snoep J.L. et al., J. Bacteriol. 174 (1994) 1707-
8; Parker C. et al., Mol. Microbiol. 15 (1995) 795-82;
Weisser P. et al., J. Bacteriol. 177 (1995) 3351-4). After
isolating the genes and recombining them in vitro with
known low copy number vectors such as pACYC184, pACYC177,

pSC101 or pZY507 (Weisser P. et al., J. Bacteriol. 177
(1995) 3351-4), the host cell is transformed using
chemical methods, electroporation, conjugation or
transduction.

5   The isolated transaldolase gene can be
integrated, together with one or more of the genes
described within the context of the invention, in any
combination, into a gene structure or into several gene
structures. Without considering the precise allocation to

10   gene structures, this leads to combinations such as *talB*,
talB + *tktA*, *talB* + *glf*, *talB* + *glk*, *talB* + *glf* + *glk*,
talB + *tktA* + *glf*, *talB* + *tktA* + *glk* or *talB* + *tktA* +
glf + *glk*.

        Gene structures are advantageous which contain

15   at least one regulatory gene sequence which is assigned to
one of the genes. Thus, reinforcement of regulatory
elements can preferably be effected at the level of
transcription by, in particular, reinforcing the
transcription signals. This can be effected, for example,

20   by increasing the activity of the promoter or the
promoters by altering the promoter sequences which are
located upstream of the structural genes or by completely
replacing the promoters with more effective promoters.
Transcription can also be reinforced by exerting an

25   appropriate influence on a regulatory gene which is
assigned to the genes; in addition to this, however, it is
also possible to reinforce translation by, for example,
improving the stability of the messenger RNA (mRNA).

        The most suitable gene structures are those in

30   which at least one of the described genes is incorporated
such that it is under the control of an inducible
promoter. When the genes are arranged on a gene structure
according to the invention, a promoter can be located
upstream of a gene or be located, as a common promoter,

- 18 -

upstream of several genes, or use can be made of two
opposed promoters between which the genes are arranged
such that they are read off in opposite directions. In
this context, the *glf* gene, for example, can be located
5   downstream of a relatively weak promoter (e.g. P*tet*) and
other genes can be under the control of the *tac* promoter.
One or more DNA sequences can be located upstream and/or
downstream of the genes contained in a gene structure,
with or without an upstream promoter or with or without an
10   assigned regulatory gene. By means of using inducible
promoter elements, e.g. *lacI^q*/P*tac*, it is possible to
switch on new functions (induction of enzyme synthesis),
for example by adding chemical inducers such as iso-
propylthiogalactoside (IPTG).

15   The object of the invention is also achieved by
providing transformed cells which harbour a gene structure
according to the invention in replicable form.

             Within the meaning of the invention, a
transformed cell is to be understood as being any
20   microorganism which carries a gene structure according to
the invention, which gene structure brings about the
increased formation of substances in the cell. The host
cells can be transformed by means of chemical methods
(Hanahan D., J. Mol. Biol. 166 (1983) 557-580) and also by
25   means of electroporation, conjugation or transduction.

             For the transformation, it is advantageous to
employ host cells in which one or more enzymes which are
additionally involved in the synthesis of the substances
are deregulated and/or have an increased activity. A
30   microorganism strain, in particular *Escherichia coli*,
which is producing an aromatic amino acid or another
substance according to the invention is transformed with
the gene structure which contains the relevant genes. For
transforming with the gene structures, it is advantageous

- 19 -

to employ host cells in which the activity of the PEP-
dependent sugar uptake system, if present, is decreased or
switched off.

In particular, transformed cells are provided
5   which are able to produce an aromatic amino acid, with the
aromatic amino acid preferably being L-phenylalanine.

Using the novel process, and the microorganism
which has been transformed in accordance with the teaching
of the invention, a broad spectrum of substrates can be
10   employed for producing substances. Within the context of
the invention, a process for the microbial preparation of
substances is consequently also provided in which cells
which have been transformed in accordance with the
invention and in which a gene structure is present which
15   contains at least one regulatory gene sequence which is
assigned to one of the genes are cultured, with enzyme
synthesis being induced in the microorganisms after at
least 2 cell divisions (beginning of the exponential
growth phase). Consequently, the production of the micro-
20   organisms can be increased independently of their growth.

In a particularly preferred embodiment of the
novel process, transformed cells are employed which, in
addition to the intermediates of the pentose phosphate
pathway, also contain an increased availability of other
25   metabolites of central metabolism. These metabolites
include, for example, pyruvate from glycolysis or
gluconeogenesis, or oxaloacetate from the citric acid
cycle. Furthermore, the relevant compound, or its pre-
cursors, that is the precursors of pyruvate or of
30   metabolites of the citric acid cycle, such as fumarate or
malate, can be made available to the growing cells by
feeding.

The invention is explained in more detail below
with the aid of a few implementation examples. The

following strains have been deposited at DSM under the
terms of the Budapest treaty:

DSM 11210 *Escherichia coli* AT2471/pZYTT7tal
5   DSM 11209 *Escherichia coli* AT2471/pZY557tkttal
DSM 11206 *Escherichia coli* AT2471GP704glfint PTS$^+$
DSM 11205 *Escherichia coli* AT2471glfint PTS$^-$

The host organism employed, i.e. AT2471, has
10 been deposited by Taylor and Trotter (Bacteriol. Rev. 13
(1967) 332-353) in the CGSC under number 4510 and is
freely accessible.
The characteristics and the provenance of all
the microorganisms employed within the context of this
15 patent application are described in detail in Table 1.
The text which follows is intended to indicate
the materials and methods employed and to support the
invention with experimental examples and comparative
examples:
20

General methods
In the genetic studies, strains of *E. coli* were,
unless otherwise indicated, cultured on LB medium
consisting of Difco bacto-tryptone (10 g·l^{-1}), Difco yeast
25 extract (5 g·l^{-1}) and NaCl (10 g·l^{-1}). Depending on the
resistance properties of the strains employed, carbeni-
cillin (20-100 mg·l^{-1}) and/or chloramphenicol (17-34 mg·l^{-1}) was/were added to the medium if necessary. For this,
carbenicillin was first of all dissolved in water, and
30 chloramphenicol in ethanol, and the solutions were added,
after having been sterilized by filtration, to the
previously autoclaved medium. Difco bacto-agar (1.5%) was
added to the LB medium for preparing agar plates.
Plasmid DNA was isolated from *E. coli* by means of alkaline

lysis using a commercially available system (Quiagen, Hilden). Chromosomal DNA was isolated from *E. coli* and *Z. mobilis* as described by Chen and Kuo (Nucl. Acid Res. 21 (1993) 2260).

5   Restriction enzymes, DNA polymerase I, alkaline phosphatase, RNase and T4 DNA ligase were used in accordance with the producers' instructions (Boehringer, Mannheim, Germany or Promega, Heidelberg, Germany). For restriction analysis, the DNA fragments were fractionated

10   in agarose gels (0.8%) and isolated from the agarose by means of extraction using a commercially available system (Jetsorb Genomed, Bad Oeynhausen, Germany).

          For Southern analyses, chromosomal DNA (10 µg) was digested with restriction enzymes, size-fractionated

15   by gel electrophoresis and transferred to a nylon membrane (Nytran 13, Schleicher and Schuell, Dassel, Germany) by means of vacuum-mediated diffusion (VacuGene System, Pharmacia, Freiburg, Germany). Appropriate DNA fragments were isolated, labelled with digoxigenin-dUTP and used as

20   probes. Labelling, hybridization, washing procedures and detection were performed with the aid of a commercially available labelling and detection system (Boehringer, Mannheim, Germany).

          For transformation, the cells were incubated at

25   37°C and 200 rpm for 2.5-3 h in LB medium (5 ml tubes). At an optical density (620 nm) of approx. 0.4, the cells were centrifuged down and taken up in one tenth the volume of TSS (LB medium containing 10% (w/v) PEG 8000, 5% (v/v) DMSO and 50 mM $MgCl_2$). After a 30-minute incubation at 4°C

30   with from 0.1 to 100 ng of DNA, and subsequent incubation at 37°C for 1 h, the cells were plated out on LB medium containing an appropriate antibiotic.

Example 1

- 22 -

Preparation of pZY557tal, pBM20tal and pZY557tkttal as
prototypes of plasmid-based gene structures according to
the invention, and of pZY557tkt

Plasmid pZY507 (Weisser et al. 1995 J. Bacteriol
5   177: 3351-3345) was opened using the restriction enzymes
BamHI and HindIII and the larger fragment (10.1 kB of DNA)
was isolated. A part of the multiple cloning site was
excised from vector pUCBM20 (Boehringer, Mannheim,
Germany) using BamHI and HindIII and ligated to the large
10   pZY507BamHI/HindIII fragment, resulting in vector pZY557,
which is similar to vector pZY507 apart from the other
restriction cleavage sites. The talB gene was amplified
from vector pGSJ451 (Sprenger G.A. et al., J. Bacteriol.
177 (1995) 5930-36) by means of PCR. For this, use was
15   made of oligonucleotide I:
5' CCGCATGCTGTTTAAAGAGAAATA 3' (the base pairs which are
underlined here correspond to base pairs 84 to 101 of the
talB sequence from Sprenger G.A. et al., J. Bacteriol. 177
(1995) 5930-6), which was provided with a cleavage site
20   for the restriction enzyme SphI, and of the commercially
obtainable M13/pUC sequencing primer (No. 1010093,
Boehringer Mannheim, Germany) as oligonucleotide II. The
resulting amplified DNA fragment contains a cleavage site
for SphI at each end and was cleaved with the restriction
25   enzyme SphI. This fragment was then ligated to vectors
pZY557 and pUCBM20, respectively, which vectors had also
been linearized with SphI. The recombinant plasmids
pZY557tal and pBM20tal, respectively, were obtained after
transforming E. coli with the two ligation solutions and
30   cloning the transformants. The tktA gene was amplified by
PCR from the vector pGSJ427 (Sprenger G.A. et al., Eur. J.
Biochem. 230 (1995) 525-32) with a cleavage site for the
restriction enzyme NotI being inserted at the 5' end and a
cleavage site for the enzyme SphI being inserted at the 3'

end. Use was made in this case of oligonucleotides III:
5'TTAGCGGCCGCCCTTCATCATCCGATCT 3' (the base pairs which
are underlined here correspond to base pairs 126 to 146 of
the *tktA* sequence from Sprenger G.A., Biochim. Biophys.
Acta. 1216 (1993) 307-10), which was provided with a
cleavage site for the restriction enzyme *NotI*, and IV: 5'
ATAGCATGCTAATTACAGCAGTTC 3' (the base pairs which are
underlined here correspond to base pairs 2018 to 2036 of
the *tktA* sequence from Sprenger G.A., Biochim. Biophys.
Acta. 1216 (1993) 307-10), which was provided with a
cleavage site for *SphI*. The resulting PCR fragment was
cleaved with *NotI* and *SphI* and ligated into vector
pZY557tkt, which had been treated in the same way,
resulting in vector pZY557tkt. pZY557tkt was then opened
with *SphI* and ligated to the *SphI*-cleaved PCR fragment
containing *talB*. After transforming *E. coli* and cloning
the transformants (see above), plasmids were obtained
which contained the *tktA* gene and the *talB* gene oriented
in the same direction downstream of the *tac* promoter and
which were subsequently used as gene structure
pZY557tkttal.

The resulting transformants were stored at -80°C
on LB medium in the form of glycerol cultures (30%). When
needed, the glycerol cultures were thawed directly before
use.

Example 2
Effect of the increased activity of a transaldolase on the
growth of strains in which transketolase activity is also
increased

The growth of the *E. coli* strains AT2471,
AT2471/pZY557tkt, AT2471/pZT557tal and AT2471/pZY557tkttal
on glucose was investigated in mineral medium. This con-
sisted of Na citrate·3H$_2$O (1.0 g·l^{-1}), MgSO$_4$·7H$_2$O (0.3 g·l$^-$

^{1}), KH_2PO_4 (3.0 g·l^{-1}), K_2HPO_4 (12.0 g·l^{-1}), NaCl (0.1 g·l^{-1}), $(NH_4)_2SO_4$ (5.0 g·l^{-1}), $CaCl_2 \cdot 2H_2O$ (15.0 mg·l^{-1}), $FeSO_4 \cdot 7H_2O$ (0.75 g·l^{-1}) and L-tyrosine (0.04 g·l^{-1}). Additional minerals were added in the form of a trace element

5   solution (1 ml·l^{-1}), which was composed of $Al_2(SO_4)_3 \cdot 18H_2O$ (2.0 g·l^{-1}), $CoSO_4 \cdot 6H_2O$ (0.7 g·l^{-1}), $CuSO_4 \cdot 5H_2O$ (2.5 g·l^{-1}), H_3BO_3 (0.5 g·l^{-1}), $MnCl_2 \cdot 4H_2O$ (20.0 g·l^{-1}), $Na_2MoO_4 \cdot 2H_2O$ (3.0 g·l^{-1}), $NiSO_4 \cdot 3H_2O$ (2.0 g·l^{-1}) and $ZnSO_4 \cdot 7H_2O$ (15.0 g·l^{-1}). Vitamin B1 (5.0 mg·l^{-1}) was dissolved in

10   water and added, after having been sterilized by filtration, to the medium after the latter had been autoclaved, as were carbenicillin and/or carbenicillin and chloramphenicol as the need arose. Glucose (30 g·l^{-1}) was autoclaved separately and likewise added to the medium

15   after the latter had been autoclaved.

For the experiments, shaking flasks (1000 ml containing 100 ml of mineral medium) were inoculated with 2 ml of glycerol culture and incubated at 37°C and 150 rpm for 72 h on an orbital shaker. After reaching an optical

20   density (620 nm) of ≈ 1, the cells were induced by adding 15-100 µM IPTG. The optical density of the culture was measured at regular intervals up to this point. Under the above-described conditions, the host organism *E. coli* AT2471 reached an optical density of 1.2 after 7.25 h. The

25   increase in the activity of the transketolase in mutant AT2471/pZY557tkt led to a marked reduction in the rate of growth; while having an identical optical density at the beginning of the experiment, this strain only reached an optical density of 0.49 after 7.25 h. The growth-

30   inhibiting effect is probably attributable to the synthesis of inhibitory concentrations of metabolic intermediates of the pentose phosphate pathway.

The increase in the activity of the transaldolase in mutant AT2471/pZY557tal also led to a

marked reduction (almost as marked as in the case of the
transketolase) in the growth rate; an optical density of
0.52 was reached after 7.25 h. It was possible to reach an
optical density of 1.1 after 7.25 h by increasing the
5   activity of the transaldolase in addition to that of the
transketolase, as was effected in *E. coli*
AT2471/pZY557tkttal. This result makes it clear that
additionally increasing the activity of a transaldolase in
a strain having an increased activity of transketolase
10 cancels the negative effects of only increasing the
activity of the transketolase and permits virtually
uninhibited growth.

Example 3
15 Determination of the enzyme activities of the
transaldolase
    In order to determine the activity of the trans-
aldolase, the cells of *E. coli* AT2471, AT2471/pZY507,
AT2471/pZY557tal and AT2471/pZY557tkttal were cultured as
20 described above with, however, 3-(morpholino)propane-
sulphonic acid (MOPS, 16.7 g·l^{-1}) being added to the
medium and the phosphate concentration being lowered to
one tenth of the concentration which was employed in the
growth experiments. In order to check the induction of the
25 cells, parallel experimental mixtures were set up, one of
which mixtures was induced by adding IPTG (20 µM) after 7
cell divisions (OD ≈ 1). 20 ml of culture broth were
removed from all the mixtures directly before adding the
inducer to the relevant flasks and 3 h after the time of
30 induction and the cells were sedimented at 6000 g for
10 min at 4°C.
    The harvested cells were washed in 50 mM
glycylglycine buffer, pH 8.5, containing 1 mM
dithiothreitol, 10 mM MgCl$_2$ and 0.5 mM thiamine

diphosphate. The cells in the sediment were disrupt d by
ultrasonic treatment (Branson 250 Sonifier fitted with a
microtip) in a sonication cycle of 25% and at an intensity
of 40 watts for 4 min per ml of cell suspension. After
5   centrifuging at 18,000 g for 30 min at 4°C, the
supernatant (crude extract) was used for measuring the
activity of the transaldolase.

    The transaldolase activity in the crude extract
was determined using an enzymic test which was optically
10 coupled to the formation of NAD. For this, the crude
extract was incubated in a total volume of 1 ml containing
0.8 mM fructose 6-phosphate, 4 mM erythrose 4-phosphate
and 0.3 mM NADH in buffer (50 mM glycylglycine, pH 8.5,
1 mM dithiothreitol, 10 mM $MgCl_2$ and 0.5 mM thiamine
15 diphosphate). The resulting glyceraldehyde 3-phosphate was
reacted with the enzymes triosephosphate isomerase (9 U)
and glycerol 3-phosphate dehydrogenase (3 U), which
enzymes were also added, with the formation of NAD. The
oxidation of NADH was monitored spectrophotometrically at
20 340 nm (ε - $6.3 \cdot 10^3$ $1 \cdot mol^{-1} \cdot cm^{-1}$), with the conversion of
1 µmol of NADH being equivalent to the consumption of
1 µmol of fructose 6-phosphate. The turnover of 1 µmol of
NADH per min was defined as 1 U.

    The protein concentration in crude extracts was
25 determined as described by Bradford (Anal. Biochem. 72
(1976) 248-254) using a commercially available colour
reagent. Bovine serum albumin was used as the standard.

    Table 2 shows the results of the enzyme
measurements when using the host strain *E. coli* AT2471 and
30 its mutants which harbour one of the plasmids pZY557,
pZY557tal or pZY557tkttal. At the time of induction, the
host strain and the strain carrying the vector pZY557 were
found to have a transketolase activity of about 0.65 U·(mg
of protein)$^{-1}$. As shown for *E. coli* AT2471/pZY557, this

value increased in three hours, as the result of physio-
logical growth, to 0.8 U·(mg of protein)$^{-1}$. Due to the
absence of the *tal* gene on the vector employed, it was not
to be expected that the induction which was performed in
5   this experiment would have any effect.

In parallel experimental mixtures, *E. coli*
AT2471/pZY557tal was found to have transketolase
activities of 0.53 and 0.61 U·(mg of protein)$^{-1}$,
respectively, at the time of induction. While the value
10 for the transaldolase activity increased in 3 h to only
0.6 U·(mg of protein)$^{-1}$ when the culture was not induced,
the transaldolase activity achieved a value of 1.06 U·(mg
of protein)$^{-1}$ as a result of induction. In other
experimental mixtures, *E. coli* AT2471/pZY557tkttal was
15 used in what were otherwise identical experiments; in this
case, the transaldolase activity had increased in the
first 3 h after inducing the cells from 0.8 to 1.16 U·(mg
of protein)$^{-1}$, which corresponded to a doubling of the
activity as compared with the corresponding experiments
20 using the host strain.

Example 4
Production of substances using strains which exhibit an
increased transketolase activity in addition to the
25 increased transaldolase activity

The medium which was employed for the growth
experiments was used for determining synthetic perform-
ance. The cultures of *E. coli* AT2471 and
AT2471/pZY557tkttal were induced at an optical density of
30 1 and the period of culture was extended to 72 h. After 24
and 48 h, the pH of the cultures was measured and brought
back to the starting value of 7.2, if required, by adding
KOH (45%). In addition, samples (2 ml) were taken after
24, 48 and 72 h for determining the optical density as

well as the concentrations of glucose and L-phenylalanine.

The phenylalanine concentration was determined
by means of high pressure liquid chromatography (HPLC,
Hewlett Packard, Munich, Germany) in combination with
5   fluorescence detection (extinction 335 nm, emission
570 nm). A Nucleosil-120-8-C18 column (250 · 4.6 mm) was
used as the solid phase; the column was eluted using a
gradient (eluent A: 90% 50 mM phosphoric acid, 10%
methanol, pH 2.5; eluent B: 20% 50 mM phosphoric acid, 80%
10 methanol, pH 2.5; gradient: 0-8 min 100% A, 8-13 min 0% A,
13-19 min 100% A). The elution rate was set at
1.0 ml·min^{-1}; the column temperature was set at 40°C.
Post-column derivatization was carried out using
o-phthalic dialdehyde in a reaction capillary (14 m ·
15 0.35 mm) at room temperature. L-phenylalanine was found to
have a retention time of 6.7 min under the conditions
described.

Measurement of the glucose concentration with
enzyme test strips (Diabur, Boehringer Mannheim, Germany)
20 and, depending on the results, the subsequent addition of
2 ml of a concentrated glucose solution (500 g·l^{-1})
ensured that glucose limitation did not arise in the
experimental mixtures. After an incubation time of 48 h, a
(phenylalanine) index value of 119 was achieved after
25 inducing the host strain *E. coli* AT2471; this compares
with a phenylalanine value of 100 for the uninduced host
strain. Simply introducing the plasmid pZY557tkttal into
the host strain had the result of increasing this index
value, describing the phenylalanine concentration, to 167
30 even without inducing the cells. As the experiments show,
inducing the strain *E. coli* AT2471/pZY557tkttal resulted
in a further increase to a value of 204. This corresponded
to an increase of 71% as compared with the induced host
strain.

This result demonstrates the positive effect
according to the invention, which effect increases the
synthesis of aromatic compounds, of additionally
increasing the activity of a transketolase in strains
5   which already have an increased transaldolase activity, or
of additionally increasing the activity of the
transaldolase in strains which already have an increased
transketolase activity.

10   Example 5
Production of substances using strains having an increased
transaldolase activity
        The mutant *E. coli* AT2471/pZY557tal was cultured
in an experiment which was otherwise identical to that
15   described in Example 4. After 48 h, induction of the
strain resulted in a (phenylalanine) index value of 131,
which compares with a phenylalanine value of 100 for the
uninduced strain.
        This result clearly demonstrates the positive
20   effect which increasing the activity of a transaldolase
exerts on the synthesis of aromatic substances,
particularly after inducing in accordance with the
invention.

25   Example 6
Production of substances using PTS⁻ mutants in which a
PEP-independent sugar uptake system is being expressed in
addition to there being an increased transaldolase
activity, with the transaldolase activity being increased
30   after the introduction of the PEP-independent sugar-uptake
system.
        The *glf* gene was obtained, as described by
Weisser P. et al. (J. Bacteriol. 177 (1995) 3351-54) using
PCR (Mullis K.B. et al., Meth. Enzymol. 155 (1987) 335-

50). The complete nucleotide sequence of this gene is
available (Barnell W.O. et al., J. Bacteriol. 172 (1990)
7227-40). The *glf* gene was amplified using plasmid pZY600
as the template (Weisser P. et al., J. Bacteriol 177

5   (1995) 3351-4).

          For the purpose of integrating the *glf* gene into
genes which encode components of the *E. coli* PTS system,
plasmid pPTS1 (see Table 1) was digested with *Bgl*II and
treated with Klenow fragment. The unique cleavage site is

10   located in the *pts*I gene. The *glf* gene was isolated, as a
*Bam*HI-*Kpn*I fragment, from plasmid pBM20glfglk and likewise
treated with Klenow fragment. Clones carrying the *glf* in
the same orientation as the *pts*HI genes were obtained by
blunt-end ligation. A 4.6 kb *Pst*I fragment carrying the 3'

15   region of the *pts*H gene and *pts*I containing integrated *glf*
and *crr* was obtained from the resulting plasmid pPTSglf.
This fragment was ligated into the *Eco*RV cleavage site of
vector pGP704. Since this vector is only able to replicate
in λ*pir* strains, the vector has been integrated into the

20   chromosome by transformants which do not harbour this
phage if these transformants are able to grow on
carbenicillin. The integration was checked by Southern
blot analysis (Miller V.L. et al., J. Bacteriol. 170
(1988) 2575-83). The resulting transformants contained the

25   complete PTS genes in addition to the *glf* gene.

          The vector moiety can be recombined out in a
second homologous crossover, resulting in the loss of the
carbenicillin resistance. Since, in this case, the *pts*
genes are interrupted by the insertion of the *glf* gene,

30   the PTS is not expressed in a functional manner in these
mutants. The desired PTS⁻ mutants were selected as
follows: after subculturing the transformants, which were
still PTS⁺, several times on LB medium without
antibiotics, aliquots of the cell suspension were plated

out on LB plates containing 100 µg·l^{-1} phosphomycin. PTS⁻
mutants are able to grow on these plates. Growing clones
were streaked out on LB plates containing either phospho-
mycin or 20 µg·l^{-1} carbenicillin. Chromosomal DNA was

5   isolated from clones which still exhibited growth on the
phosphomycin plates but which were not able to grow on the
carbenicillin plates. The integration of the *glf* gene into
the genes which encode the PTS system was confirmed by
Southern analysis. Corresponding mutants were identified

10   as being phenotypically PTS-deficient. One clone was
selected as the host organism *E. coli* AT2471glfintPTS⁻ and
used for the transformations (see above) with plasmid
pZY557tal. Following the experimental conditions described
for Examples 4 and 5, the PTS-negative mutant *E. coli*

15   AT2471glfintPTS⁻/pZY557tal, and the corresponding host
strain AT2471glfintPTS⁻, were in each case cultured in two
parallel mixtures and the cells of one mixture in each
case were induced after approx. 7 divisions.

        The induction reduced the synthetic performance
20   of the host strain, which initially had an index value of
100 without induction, down to a value of 56. By
comparison, the induction increased the phenylalanine
index value from 73 to 103, and consequently above the
initial value for the host strain, in cultures of the

25   transformed strain AT2471glfintPTS⁻/pZY557tal.

        This result demonstrates that simply increasing
the transaldolase activity has a positive effect on the
synthesis of phenylalanine even in those microorganisms in
which the activity of the PTS system is diminished, or

30   this system is completely switched off, and into which, at
the same time, a PEP-independent sugar uptake system has
been integrated.

Example 7

Production of substances using PTS⁻ mutants in which in
addition to an increased transaldolase activity a PEP-
independent sugar-uptake system has been expressed, with
the transaldolase activity being increased before the
5   introduction of the PEP-independent sugar-uptake system.

        E. coli AT2471/pZY557tal was obtained as
described in Example 1. Subsequently in this strain a *glf*
gene was integrated into the genes which encode components
of the PTS system of *E. coli*. This integration was carried
10   out as described in Example 6. Using the experimental
conditions described in Examples 4 and 5, these PTS-
negative *E.coli* AT2471glfintPTS⁻/pZY557tal mutants were
cultured. It was found that the biosynthetic performance
of the derived mutants corresponded to that of the strains
15   described in Example 6.

Example 8
Production of substances in a fermentation vessel using
strains having an increased transaldolase activity and
20   strains having an increased transketolase activity in
addition to their increased transaldolase activity.

        The mutants *E. coli* AT2471, *E. coli*
AT2471/pZY557tal and *E. coli* AT2471/pZY557tkttal were
cultured in a fermentation vessel (reactor volume 15 l).
25   To this end, two shaking flasks (2000 ml) with the mineral
medium described in Example 2 (250 ml) were used for
preculturing. In this process, the glucose concentration
was reduced to 5.0 g.l⁻¹. The flasks were inoculated with
2 ml of glycerol culture and incubated on an orbital
30   shaker at 37°C and 150 rpm until an optical density (600
nm) of 3 was reached.

        The precultures were used for inoculating 4.5 l
of production medium. This contained $MgSO_4 \cdot 7H_2O$ (0.3 g·l⁻¹), KH_2PO_4 (3.0 g·l⁻¹), NaCl 0.1 (g·l⁻¹), $(NH_4)_2SO_4$ (5.0 g·l⁻¹

^{1}), $CaCl_2 \cdot 2H_2O$ (15.0 mg·l^{-1}), $FeSO_4 \cdot 7H_2O$ (0.75 gl^{-1}) and L-tyrosine (0.24 g·l^{-1}). Additional minerals were added in the form of a trace element solution (1.5 ml·l^{-1}), which was composed of $Al_2(SO_4)_3 \cdot 18H_2O$ (2.0 g·l^{-1}), $CoSO_4 \cdot 6H_2O$

5   (0.7 g·l^{-1}), $CuSO_4 \cdot 5H_2O$ (2.5 g·l^{-1}), H_3BO_3 (0.5 g·l^{-1}), $MnCl_2 \cdot 4H_2O$ (20.0 g·l^{-1}), $Na_2MoO_4 \cdot 2H_2O$ (3.0 g·l^{-1}), $NiSO_4 \cdot 3H_2O$ (2.0 g·l^{-1}) and $ZnSO_4 \cdot 7H_2O$ (15.0 g·l^{-1}). Vitamin B1 (75.0 mg·l^{-1}) was dissolved in water and added, after having been sterilized by filtration, to the medium after

10   the latter had been autoclaved. Glucose (15 g·l^{-1}) was autoclaved separately and likewise added to the medium after the latter had been autoclaved. By adding NH_4OH (25%) the pH value in the medium was controlled at 7, the oxygen partial pressure being controlled at a value of 20%

15   via the stirrer speed, the air volume fed and the pressure inside the fermentation vessel. By adding a glucose solution (700 g·l^{-1}) the glucose concentration in the culture medium was kept at values around 5 g.l^{-1}. Depending on the fermentation time, L-tyrosine was added

20   to the glucose solution in variable concentrations in order to avoid L-tyrosine limitation.

In experiments in which cell induction was effected, this was done in accordance with the invention after 6 hours by adding 50 µM of IPTG. After an incubation

25   time of 36 hours, a (phenylalanine) index value of 120 was achieved by simply introducing the pZY557tal plasmid; this compares with a (phenylalanine) index value of 100 for the uninduced host strain *E. coli* AT2471. By means of induction according to the invention this value could be

30   raised further to 153. By introducing the pZY557tkttal plasmid alone and thus raising the transketolase activity in addition to the transaldolase activity, a (phenylalanine) index value of 130 could be achieved compared with the host strain. The experiments further

- 34 -

showed that the induction of the strain *E. coli* AT2471/pZY557kttal enabled a further increase in the (phenylalanine) index value to 250. This corresponds to an increase of 92% compared with the uninduced strain.

5   This result shows that even in experiments carried out in fermentation vessels an increase in the synthesis of aromatic compounds can be achieved according to the invention by increasing the transaldolase activity as well as by increasing the transketolase activity in

10   strains which already have an increased transaldolase activity.

Table 1:

Strains and plasmids	Genotype/ characteristics	Source or reference
E.coli AT2471	*tyr*A4, *rel*A1, *spo*T1, *thi*-1	Taylor and Trotter, Bacteriol. Rev. 13 (1967) 332-53
E. coli SY327	araD, Δ(lac-*pro*), Rif^r, recA56, λ-phage *pir* function	Miller et al., J. Bacteriol. 170 (1988) 2575-83
E. coli CC118	Δ(*ara-leu*), araD, ΔlacX74, *gal*E, *gal*K, phoA20, *thi*-1, *rps*E, *rpo*B, *arg*E (Am), *rec*A1, λ*pir* lysogen	Manoil et al., Proc. Natl. Acad. Sci USA 82 (1985) 8129-33
pZY507	Cm^r	Weisser et al., J. Bacteriol 177 (1995) 3351-4
pZY507glfglk	Z. mobilis *glf* and glk genes in p-ZY507	Weisser et al., J. Bacteriol 177 (1995) 3351-4
pZY557	pZY507, multiple cloning site of pUCBM20, Cm^r	Sprenger, unpublished
pZY557tkttal	*E. coli tkt*A and *tal*B genes in pZY557	This patent application

Strains and plasmids	Genotype/ characteristics	Source or reference
pACYC184	Cm^r, Tet^r	Chang and Cohen, J. Bacteriol. 134 (1978) 1141-1156
pDIA3206	Ap^r, 11.5 kb insert from *E. coli* K12 chromosome including *ptsHI-crr* genes	DeReuse et al., J. Bacteriol. 170 (1988) 3827-37
pPTS1	pACYC184 containing a 4 kb *ClaI* fragment which contains the *ptsHI* and *crr* genes from pDIA3206; Cm^r	Jahreis, Osnabruck university, unpublished
pGP704	Amp^r	Miller et al., J. Bacteriol. 170 (1988) 2575-83

5

Table 2

Microorganism	Time after induction/ h	Transaldolase activity/ U·(mg of protein)$^{-1}$	
		without induction	with induction
E. coli AT2471/	0		0.64
E. coli AT2471/ pZY557	0 3		0.65 0.80
E. coli AT2471/ pZY557tal	0 3	0.53 0.6	0.61 1.06
E. coli AT2471/ pZY557tkttal	0 3	0.70 0.45	0.80 1.16

- 38 -

C L A I M S

1. Process for the microbial preparation of substances
    in which the activity of a transaldolase is increased
    in a microorganism which is producing these
    substances, with the activity of a
    phosphoenolpyruvate (PEP)-dependent sugar-uptake
    system in this microorganism being present, reduced
    or absent.

2. Process according to Claim 1, characterized in that
    the preparation of substances is effected in
    microorganisms which have not, prior to the
    increasing of the transaldolase activity, been
    selected as strains with a switched-off
    phosphotransferase system (pts⁻ strains) from strains
    which previously harboured a phosphotransferase
    system (pts⁺ strains).

3. Process according to Claim 1 or 2, characterized in
    that substances are prepared in whose synthesis at
    least one intermediate of the pentose phosphate
    pathway is involved.

4. Process according to Claim 3, characterized in that
    the intermediate is erythrose 4-phosphate (Ery4P).

5. Process according to Claim 1 or 4, characterized in
    that the activity of an *Escherichia coli*
    transaldolase is increased.

6. Process according to one of Claims 1 to 5,
    characterized in that the activity of *Escherichia
    coli* transaldolase B (TalB) is increased.

7. Process according to one of Claims 1 to 6,
    characterized in that the activity of a transketolase
    is additionally increased.

8. Process according to Claim 7, characterized in that
    the activity of an *Escherichia coli* transketolase is

- 39 -

increased.

9. Process according to one of Claims 7 or 8, characterized in that the activity of *Escherichia coli* transketolase A (TktA) is increased.

5   10. Process according to one of Claims 1 to 9, characterized in that the activity of a transport protein for the PEP-independent uptake of a sugar and/or the activity of a kinase which phosphorylates the relevant sugar are/is additionally increased.

10   11. Process according to Claim 10, characterized in that the transport protein is a facilitator.

12. Process according to Claim 11, characterized in that the facilitator is the *Zymomonas mobilis* glucose facilitator protein (Glf).

15   13. Process according to one of Claims 10 to 12, characterized in that the kinase is a hexose-phosphorylating kinase.

14. Process according to Claim 13, characterized in that the kinase is derived from *Zymomonas mobilis*.

20   15. Process according to Claim 14, characterized in that the kinase is *Zymomonas mobilis* glucokinase (Glk).

16. Process according to one of Claims 10 to 15, characterized in that the activity of a PEP-dependent sugar uptake system, if present, is additionally

25   decreased or switched off.

17. Process according to one of Claims 1 to 16, characterized in that the activity of at least one of the following components, i.e. transaldolase, transketolase, transport protein and kinase, is

30   increased

a)   by introduction of the genes

b)   and/or by increasing the gene copy number

c)   and/or by increasing gene expression

d)   and/or by increasing the endogenous activity of

the said enzymes

e)   and/or by altering the structure of the enzymes

f)   and/or by using deregulated enzymes

g)   and/or by inserting genes which encode
     deregulated enzymes.

18.   Process according to Claim 17, characterized in that
      the increase in the activity is achieved by inte-
      grating the gene or the genes into a gene structure
      or into several gene structures, with the gene or the
      genes being introduced into the gene structure as (a)
      single copy(ies) or in increased copy number.

19.   Process according to one of Claims 1 to 18,
      characterized in that a microorganism is employed in
      which one or more enzymes, which are additionally
      involved in the synthesis of the substances, are
      deregulated and/or exhibit increased activity.

20.   Process according to Claims 1 to 19, characterized in
      that the substance which is prepared is an aromatic
      amino acid.

21.   Process according to Claim 20, characterized in that
      the aromatic amino acid is L-phenylalanine.

22.   Process according to one of Claims 1 to 21,
      characterized in that the microorganism employed
      belongs to the genus *Escherichia, Serratia, Bacillus,*
      Corynebacterium or *Brevibacterium.*

23.   Process according to Claim 22, characterized in that
      the microorganism is *Escherichia coli.*

24.   Gene structure containing, in recombinant form,

      a)   a gene encoding a transaldolase or a gene
           encoding a transaldolase and a gene encoding a
           transketolase, and

      b)   at least one gene encoding a transport protein
           for the PEP-independent uptake of a sugar or
           encoding a sugar-phosphorylating kinase.

25. Gene structure according to Claim 24, characterized in that the gene for the transport protein encodes a facilitator and the gene for the kinase encodes a hexose-phosphorylating kinase.

26. Gene structure according to Claim 24 or 25, characterized in that the genes for the transaldolase and the transketolase are derived from *Escherichia coli* and the genes for the transport protein and the kinase are derived from *Zymomonas mobilis*.

27. Gene structure according to Claims 24 to 26, characterized in that the gene for the *Escherichia coli* transaldolase is *talB* and the gene for the *Escherichia coli* transketolase is *tktA*, and the gene for the *Zymomonas mobilis* transport protein is *glf* and the gene for the *Zymomonas mobilis* kinase is *glk*.

28. Gene structure according to one of Claims 24 to 27, characterized in that the gene structure contains at least one regulatory gene sequence which is assigned to one of the genes.

29. Gene structure according to Claim 28, characterized in that at least one of the genes in the gene structure is incorporated such that it is under the control of an inducible promoter.

30. Transformed cell, harbouring, in replicable form, a gene structure according to Claims 24 to 29.

31. Transformed cell according to Claim 30, characterized in that, in the cell, one or more enzymes which are additionally involved in the synthesis of the substances are deregulated and/or exhibit increased activity.

32. Transformed cell according to Claim 30 or 31, characterized in that the cell is an *Escherichia coli* cell.

33. Transformed cell according to one of Claims 30 to 32,

characterized in that the activity of the PEP-
dependent sugar uptake system, if this system is
present, is decreased or switched off.

34. Transformed cell according to one of Claims 30 to 33,
characterized in that it is able to produce an
aromatic amino acid.

35. Transformed cell according to Claim 34, characterized
in that the aromatic amino acid is L-phenylalanine.

36. Process for the microbial preparation of substances
according to one of Claims 1 to 23, characterized in
that transformed cells according to one of Claims 30
to 35, in which there is a gene structure according
to Claim 29, are cultured, with the induction being
effected after 2 cell divisions at the earliest.

37. Process according to Claim 36, characterized in that,
in addition to the intermediates of the pentose
phosphate pathway, the transformed cell also contains
other metabolites of central metabolism in increased
availability.

INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/54 C12P13/22 C12P19/02 C12P1/00 C12N15/31
        C07H11/04 C12N1/21 //C12Q1/48,(C12N1/21,C12R1:07,1:13,
        1:15,1:185,1:19,1:425)

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C12P C07K C07H C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LIAO J.C. ET AL.: "Pathway analysis, engineering, and physiological considerations for redirecting central metabolism" BIOTECHNOLOGY AND BIOENGINEERING, vol. 52, no. 1, 5 October 1996, pages 129-140, XP002053640 cited in the application	1-4,7-9, 17-23
Y	see abstract see page 130, right-hand column, paragraph 4 see page 132 - page 133 --- -/--	5,6, 10-16, 24-37

[X] Further documents are listed in the continuation of box C.   [X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
5 February 1998	20/02/1998

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Macchia, G

Form PCT/ISA/210 (second sheet) (July 1992)

page 1 of 3

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
Y	FROST J.W. AND DRATHS K.M.: "Biocatalytic syntheses of aromatics from D-glucose: renewable microbial sources of aromatic compounds" ANNUAL REVIEW OF MICROBIOLOGY, vol. 49, 1995, pages 557-579, XP002053641 see page 561 - page 564 ---	1-37
Y	SPRENGER G.A. ET AL.: "Transaldolase B of Escherichia coli K-12: cloning of its gene, talB, and characterization of the enzyme from recombinant strains" JOURNAL OF BACTERIOLOGY, vol. 177, no. 20, October 1995, pages 5930-5936, XP002053305 cited in the application see page 5930, left-hand column, line 1-18 see page 5934, left-hand column; table 2 see page 5935, right-hand column, line 8-21 ---	1-37
P,X	LU J.-L. AND LIAO J.C.: "Metabolic engineering and control analysis for production of aromatics: role of transaldolase" BIOTECHNOLOGY AND BIOENGINEERING, vol. 53, no. 2, 20 January 1997, pages 132-138, XP002053307 see abstract ---	1-9, 17-23
E	WO 96 34961 A (GENENCOR INT ;UNIV MEXICO (MX)) 7 November 1996 cited in the application see abstract see page 1, paragraph 4 - page 4, paragraph 1 ---	1,3,4, 7-10, 16-23
X	ZHANG M. ET AL.: "METABOLIC ENGINEERING OF A PENTOSE METABOLISM PATHWAY IN ETHANOLOGENIC ZYMOMONAS MOBILIS" SCIENCE, vol. 267, 13 January 1995, pages 240-243, XP002026045 see page 241 - page 242 ---	1,3-10, 17-19, 24, 28-31, 33,36,37

-/--

4

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
X	WALFRIDSSON M. ET AL.: "Xylose-metabolizing Saccharomyces cerevisiae strains overexpressing the tkl1 and tal1 genes encoding the pentose phosphate pathway enzymes transketolase and transaldolase" APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 61, no. 12, December 1995, pages 4184-4190, XP002053306 see page 4185, left-hand column; figure 1 see page 4188, right-hand column, line 14 - page 4189, left-hand column, line 2 ---	1,3,4,7, 17-19
A	BERRY A.: "Improving production of aromatic compounds in Escherichia coli by metabolic engineering" TRENDS IN BIOTECHNOLOGY, vol. 14, no. 7, July 1996, page 250-256 XP004035764 see page 252, right-hand column, paragraph 2 - page 255, right-hand column, paragraph 1 ---	1-10,13, 15-37
A	GOSSET G. ET AL.: "A direct comparison of approaches for increasing carbon flow to aromatic biosynthesis in Escherichia coli" JOURNAL OF INDUSTRIAL MICROBIOLOGY, vol. 17, no. 1, July 1996, pages 47-52, XP002054313 see abstract see page 50; table 2 ---	1,2
A	WEISSER P. ET AL.: "Functional expression of the glucose transporter of Zymomonas mobilis leads to restoration of glucose and fructose uptake in Escherichia coli mutants and provides evidence for its facilitator action" JOURNAL OF BACTERIOLOGY, vol. 177, no. 11, June 1995, pages 3351-3354, XP002053706 cited in the application -----	

4

page 3 of 3

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9634961 A	07-11-96	NONE	